Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer

L. Trodella; F. De Marinis; R. M. D'Angelillo; S. Ramella; A. Cesario; S. Valente; F. Nelli; M. R. Migliorino; S. Margaritora; G. M. Corbo; V. Porziella; M. Ciresa; F. Cellini; S. Bonassi; P. Russo; E. Cortesi; P. Granone

doi:10.1016/j.lungcan.2006.07.020

Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer

L. Trodella, F. De Marinis, R. M. D'Angelillo, S. Ramella, A. Cesario, S. Valente, F. Nelli, M. R. Migliorino, S. Margaritora, G. M. Corbo, V. Porziella, M. Ciresa, F. Cellini, S. Bonassi, P. Russo, E. Cortesi, P. Granone

Research output: Contribution to journal › Article › peer-review

Abstract

Background: To evaluate feasibility and safety of induction three-drugs combination chemotherapy and concurrent radio-chemotherapy in stage IIIB NSCLC. Patients and Methods: Patients with stage IIIB NSCLC were treated with three courses of induction chemotherapy, cisplatin 50 mg/m², paclitaxel 125 mg/m² and gemcitabine 1000 mg/m² on days 1,8 of every 21 day cycle. Patients without distant progressive disease were then treated with radiotherapy and concurrent weekly gemcitabine (250 mg/m²). Toxicity and response of radio-chemotherapy treatment have been assessed. Results: Between Jan 01 and Nov 02, 46 patients were enrolled. Grade 3+ hematological and non-hematological toxicity during the induction phase were 41.3% and 13.1%, respectively. In 38 patients a Clinical Response or Stable Disease was recorded and these patients underwent to concurrent radio-chemotherapy. Grade 3+ hematological and non-hematological toxicities were 8.2% in this group. Further response was observed in 66% of patients. Overall median survival time was 17.8 months, with a 3-year survival rates of 23%. Conclusion: Three-drugs induction chemotherapy and concurrent radio-chemotherapy with weekly gemcitabine in locally advanced stage IIIB NSCLC is feasible and safe.

Original language	English
Pages (from-to)	331-338
Number of pages	8
Journal	Lung Cancer
Volume	54
Issue number	3
DOIs	https://doi.org/10.1016/j.lungcan.2006.07.020
Publication status	Published - Dec 2006

Keywords

Chemoradiation
Concurrent radio-chemotherapy
Conformal radiotherapy
Gemcitabine
Induction chemotherapy
Locally advanced disease
Non-small cell lung cancer
Phase II trial

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/j.lungcan.2006.07.020

Fingerprint Dive into the research topics of 'Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this

Trodella, L., De Marinis, F., D'Angelillo, R. M., Ramella, S., Cesario, A., Valente, S., Nelli, F., Migliorino, M. R., Margaritora, S., Corbo, G. M., Porziella, V., Ciresa, M., Cellini, F., Bonassi, S., Russo, P., Cortesi, E., & Granone, P. (2006). Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. Lung Cancer, 54(3), 331-338. https://doi.org/10.1016/j.lungcan.2006.07.020

Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. / Trodella, L.; De Marinis, F.; D'Angelillo, R. M.; Ramella, S.; Cesario, A.; Valente, S.; Nelli, F.; Migliorino, M. R.; Margaritora, S.; Corbo, G. M.; Porziella, V.; Ciresa, M.; Cellini, F.; Bonassi, S.; Russo, P.; Cortesi, E.; Granone, P.

In: Lung Cancer, Vol. 54, No. 3, 12.2006, p. 331-338.

Research output: Contribution to journal › Article › peer-review

Trodella, L, De Marinis, F, D'Angelillo, RM, Ramella, S, Cesario, A, Valente, S, Nelli, F, Migliorino, MR, Margaritora, S, Corbo, GM, Porziella, V, Ciresa, M, Cellini, F, Bonassi, S , Russo, P, Cortesi, E & Granone, P 2006, 'Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer', Lung Cancer, vol. 54, no. 3, pp. 331-338. https://doi.org/10.1016/j.lungcan.2006.07.020

Trodella, L. ; De Marinis, F. ; D'Angelillo, R. M. ; Ramella, S. ; Cesario, A. ; Valente, S. ; Nelli, F. ; Migliorino, M. R. ; Margaritora, S. ; Corbo, G. M. ; Porziella, V. ; Ciresa, M. ; Cellini, F. ; Bonassi, S. ; Russo, P. ; Cortesi, E. ; Granone, P. / Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. In: Lung Cancer. 2006 ; Vol. 54, No. 3. pp. 331-338.

@article{5f898e20e7c2477fbc47ddeaf81de529,

title = "Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer",

abstract = "Background: To evaluate feasibility and safety of induction three-drugs combination chemotherapy and concurrent radio-chemotherapy in stage IIIB NSCLC. Patients and Methods: Patients with stage IIIB NSCLC were treated with three courses of induction chemotherapy, cisplatin 50 mg/m2, paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on days 1,8 of every 21 day cycle. Patients without distant progressive disease were then treated with radiotherapy and concurrent weekly gemcitabine (250 mg/m2). Toxicity and response of radio-chemotherapy treatment have been assessed. Results: Between Jan 01 and Nov 02, 46 patients were enrolled. Grade 3+ hematological and non-hematological toxicity during the induction phase were 41.3% and 13.1%, respectively. In 38 patients a Clinical Response or Stable Disease was recorded and these patients underwent to concurrent radio-chemotherapy. Grade 3+ hematological and non-hematological toxicities were 8.2% in this group. Further response was observed in 66% of patients. Overall median survival time was 17.8 months, with a 3-year survival rates of 23%. Conclusion: Three-drugs induction chemotherapy and concurrent radio-chemotherapy with weekly gemcitabine in locally advanced stage IIIB NSCLC is feasible and safe.",

keywords = "Chemoradiation, Concurrent radio-chemotherapy, Conformal radiotherapy, Gemcitabine, Induction chemotherapy, Locally advanced disease, Non-small cell lung cancer, Phase II trial",

author = "L. Trodella and {De Marinis}, F. and D'Angelillo, {R. M.} and S. Ramella and A. Cesario and S. Valente and F. Nelli and Migliorino, {M. R.} and S. Margaritora and Corbo, {G. M.} and V. Porziella and M. Ciresa and F. Cellini and S. Bonassi and P. Russo and E. Cortesi and P. Granone",

year = "2006",

month = dec,

doi = "10.1016/j.lungcan.2006.07.020",

language = "English",

volume = "54",

pages = "331--338",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer

AU - Trodella, L.

AU - De Marinis, F.

AU - D'Angelillo, R. M.

AU - Ramella, S.

AU - Cesario, A.

AU - Valente, S.

AU - Nelli, F.

AU - Migliorino, M. R.

AU - Margaritora, S.

AU - Corbo, G. M.

AU - Porziella, V.

AU - Ciresa, M.

AU - Cellini, F.

AU - Bonassi, S.

AU - Russo, P.

AU - Cortesi, E.

AU - Granone, P.

PY - 2006/12

Y1 - 2006/12

N2 - Background: To evaluate feasibility and safety of induction three-drugs combination chemotherapy and concurrent radio-chemotherapy in stage IIIB NSCLC. Patients and Methods: Patients with stage IIIB NSCLC were treated with three courses of induction chemotherapy, cisplatin 50 mg/m2, paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on days 1,8 of every 21 day cycle. Patients without distant progressive disease were then treated with radiotherapy and concurrent weekly gemcitabine (250 mg/m2). Toxicity and response of radio-chemotherapy treatment have been assessed. Results: Between Jan 01 and Nov 02, 46 patients were enrolled. Grade 3+ hematological and non-hematological toxicity during the induction phase were 41.3% and 13.1%, respectively. In 38 patients a Clinical Response or Stable Disease was recorded and these patients underwent to concurrent radio-chemotherapy. Grade 3+ hematological and non-hematological toxicities were 8.2% in this group. Further response was observed in 66% of patients. Overall median survival time was 17.8 months, with a 3-year survival rates of 23%. Conclusion: Three-drugs induction chemotherapy and concurrent radio-chemotherapy with weekly gemcitabine in locally advanced stage IIIB NSCLC is feasible and safe.

AB - Background: To evaluate feasibility and safety of induction three-drugs combination chemotherapy and concurrent radio-chemotherapy in stage IIIB NSCLC. Patients and Methods: Patients with stage IIIB NSCLC were treated with three courses of induction chemotherapy, cisplatin 50 mg/m2, paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on days 1,8 of every 21 day cycle. Patients without distant progressive disease were then treated with radiotherapy and concurrent weekly gemcitabine (250 mg/m2). Toxicity and response of radio-chemotherapy treatment have been assessed. Results: Between Jan 01 and Nov 02, 46 patients were enrolled. Grade 3+ hematological and non-hematological toxicity during the induction phase were 41.3% and 13.1%, respectively. In 38 patients a Clinical Response or Stable Disease was recorded and these patients underwent to concurrent radio-chemotherapy. Grade 3+ hematological and non-hematological toxicities were 8.2% in this group. Further response was observed in 66% of patients. Overall median survival time was 17.8 months, with a 3-year survival rates of 23%. Conclusion: Three-drugs induction chemotherapy and concurrent radio-chemotherapy with weekly gemcitabine in locally advanced stage IIIB NSCLC is feasible and safe.

KW - Chemoradiation

KW - Concurrent radio-chemotherapy

KW - Conformal radiotherapy

KW - Gemcitabine

KW - Induction chemotherapy

KW - Locally advanced disease

KW - Non-small cell lung cancer

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=33750390862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750390862&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.07.020

DO - 10.1016/j.lungcan.2006.07.020

M3 - Article

C2 - 17011065

AN - SCOPUS:33750390862

VL - 54

SP - 331

EP - 338

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -